Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
LOC
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1
EP3054971B1
EPSTEIN-BARR VIRUS VACCINES
Publication/Patent Number: EP3054971B1 Publication Date: 2021-03-10 Application Number: 14799574.0 Filing Date: 2014-10-10 Inventor: Kanekiyo, Masaru   Nabel, Gary J.   Cohen, Jeffrey   Bu, Wei   Assignee: The United States of America, represented by the Secretary, Department of Health and Human Services   IPC: A61K39/12
2
EP3842068A1
NOVEL PRIME-BOOSTING REGIMENS INVOLVING IMMUNOGENIC POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES
Publication/Patent Number: EP3842068A1 Publication Date: 2021-06-30 Application Number: 20213823.6 Filing Date: 2013-07-05 Inventor: Nicosia, Alfredo   Cortese, Ricardo   Vitelli, Alessandra   Assignee: GlaxoSmithKline Biologicals S.A.   IPC: A61K39/12 Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.
3
US2021046173A1
RSV RNA VACCINES
Publication/Patent Number: US2021046173A1 Publication Date: 2021-02-18 Application Number: 16/965,589 Filing Date: 2019-01-28 Inventor: Ciaramella, Giuseppe   Bahl, Kapil   Espeseth, Amy   Bett, Andrew J.   Cejas, Pedro   Zhang, Lan   Shaw, Christine   Assignee: ModernaTX, Inc.   IPC: A61K39/12 Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
4
EP3512936B1
GENERATION OF HPV-SPECIFIC T-CELLS
Publication/Patent Number: EP3512936B1 Publication Date: 2021-04-28 Application Number: 17772645.2 Filing Date: 2017-09-15 Inventor: Ramos, Carlos A.   Rooney, Cliona M.   Narala, Neeharika   Assignee: Baylor College of Medicine   IPC: A61K39/12
5
EP3773710A1
T-CELL INDUCING VACCINE COMPOSITION COMBINATIONS AND USES THEREOF
Publication/Patent Number: EP3773710A1 Publication Date: 2021-02-17 Application Number: 19780597.1 Filing Date: 2019-04-04 Inventor: Georges, Bertrand   Roberts, Scot   Assignee: Altimmune Inc   IPC: A61K39/12
6
EP2764011B1
ADENOVIRAL VECTOR-BASED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE
Publication/Patent Number: EP2764011B1 Publication Date: 2021-04-07 Application Number: 12773193.3 Filing Date: 2012-10-05 Inventor: Brough, Douglas E.   Gall, Jason G.d.   Mcvey, Duncan   Assignee: GenVec, Inc.   IPC: A61K39/12
7
CN105451763B
用于疫苗中的登革热病毒嵌合式构建物的组合物及方法
Grant
Publication/Patent Number: CN105451763B Publication Date: 2021-06-18 Application Number: 201480028001.5 Filing Date: 2014-03-12 Inventor: 丹·t·斯廷奇科姆   克莱尔·凯尼   理查德·m·凯尼   吉尔·a·利文格德   Assignee: 武田疫苗股份有限公司   美国政府健康及人类服务部   IPC: A61K39/12 Abstract: 本文的实施方案报告了登革热病毒构建物和活减毒登革热病毒的组合物、用途及制造。一些实施方案涉及这样的组合物,其包括但不限于四价登革热病毒组合物。在某些实施方案中,组合物可包含登革热病毒的一种或多种血清型的构建物,诸如登革热‑1(DEN‑1)病毒、登革热‑2(DEN‑2)病毒、登革热‑3(DEN‑3)病毒或登革热‑4(DEN‑4)病毒的构建物。在其它实施方案中,本文所公开的构建物可组合于组合物中以产生对抗多于一种或多种登革热病毒构建物的疫苗,该构建物可以或可以不接续地在哺乳动物细胞内传代。
8
CN113301918A
CMV的通过融合修饰的病毒样颗粒
Public
Publication/Patent Number: CN113301918A Publication Date: 2021-08-24 Application Number: 201980084939.1 Filing Date: 2019-12-20 Inventor: A·泽尔汀斯   Assignee: 塞坝股份公司   IPC: A61K39/12 Abstract: 本发明涉及一种黄瓜花叶病毒(CMV)的经修饰的病毒样颗粒(VLP),其包括至少一种融合蛋白,其中所述至少一种融合蛋白包括b)嵌合CMV多肽或优选地由其组成,其中所述嵌合CMV多肽包括以下或优选地由以下组成:(iii)CMV多肽,其中所述CMV多肽包括CMV的外壳蛋白或优选地由其组成,其中优选地CMV的所述外壳蛋白包括以下或优选地由以下组成:SEQ ID NO:62;或与SEQ ID NO:62具有至少75%、优选地至少80%、更优选地至少85%、再进一步优选地至少90%、再更优选地至少95%、仍进一步优选地至少98%以及仍再进一步更优选地至少99%的序列同一性的氨基酸序列;以及(iv)抗原多肽,其中所述抗原多肽插入到所述CMV多肽中,其中所述抗原多肽的所述插入处于所述CMV多肽的与SEQ ID NO:62的位置84和位置85的氨基酸残基对应的氨基酸残基之间;以及(iii)T辅助细胞表位,其中所述T辅助细胞表位替代所述CMV多肽的N端区域,并且其中优选地所述CMV多肽的所述N端区域对应于SEQ ID NO:62的氨基酸2‑12。
9
EP3892296A1
IMMUNOGENIC COMPOSITION COMPRISING AN ANTIGENIC MOIETY AND A LIPOSOMAL FORMULATION, METHOD OF PRODUCING THE COMPOSITION, THE COMPOSITION FOR USE AS A MEDICAMENT, IN PARTICULAR FOR USE AS A VACCINE
Publication/Patent Number: EP3892296A1 Publication Date: 2021-10-13 Application Number: 20168554.2 Filing Date: 2020-04-07 Inventor: Halbherr, Stéfan Jonathan   Peitsch, Camille   Assignee: InnoMedica Holding AG   IPC: A61K39/12 Abstract: The present invention concerns an immunogenic composition comprising (a) an antigenic moiety, preferably an antigenic moiety being or comprising an amino acid sequence corresponding to a surface protein domain of SARS-CoV-2 virus; and (b) a liposomal formulation as an adjuvant. More specifically, the antigenic moiety preferably is either the receptor binding domain RBD of Spike protein S of SARS-CoV-2 virus, or the HR domain of S2 subunit of spike protein S of SARS-CoV-2 virus; or an immunogenic fragment thereof.
10
US2021052718A1
RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES
Publication/Patent Number: US2021052718A1 Publication Date: 2021-02-25 Application Number: 17/043,979 Filing Date: 2019-03-29 Inventor: Kang, Sang-moo   Lee, Youri   Ko, Eunju   Kwon, Young-man   Kim, Ki-hye   Assignee: Georgia State University Research Foundation, Inc.   IPC: A61K39/12 Abstract: Disclosed are vaccines capable of achieving protection against RSV while avoiding vaccine-enhanced disease (VED). In particular, vaccine constructs have been molecularly designed and genetically engineered to comprise RSV fusion (F) protein displayed on the surface of a particle, such as a virus-like particles (VLP) and low temperature-prepared split RSV. In some embodiments, the RSV F protein is in a pre-fusion F conformation. Also disclosed a variants and combinations of split RSV and RSV F DNA vaccine with pre-fusion F and enhanced efficacy. In addition, disclosed split RSV vaccines containing pre-fusion F conformation and combination adjuvants MPL and CpG.
11
EP3838290A1
VACCINE COMPOSITIONS COMPRISING AN ATTENUATED MUTANT ZIKA VIRUS
Publication/Patent Number: EP3838290A1 Publication Date: 2021-06-23 Application Number: 20212555.5 Filing Date: 2017-06-22 Inventor: Despres, Philippe   Gadea, Gilles   Mavingui, Patrick   Viranaicken, Wildriss   Assignee: INSERM (Institut National de la Santé et de la Recherche Médicale)   Université de la Réunion Saint Denis   Institut De Recherche Pour Le Développement (IRD)   Centre National de la Recherche Scientifique (CNRS)   IPC: A61K39/12 Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
12
US2021236620A1
COMPOSITIONS AND METHODS OF VACCINATION AGAINST DENGUE VIRUS IN CHILDREN AND YOUNG ADULTS
Publication/Patent Number: US2021236620A1 Publication Date: 2021-08-05 Application Number: 17/229,109 Filing Date: 2021-04-13 Inventor: Wallace, Derek   Boslego, John   Assignee: TAKEDA VACCINES, INC.   IPC: A61K39/12 Abstract: Embodiments herein concern compositions, methods, and uses for inducing an immune response to all four dengue virus serotypes in a child or young adult from about 1 year to about 20 years of age. Some embodiments concern compositions that can include dengue virus chimeras that, either alone or in combination with other constructs, can be used in vaccine compositions against all four dengue virus serotypes. Compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) virus and/or dengue-4 (DEN-4) virus, at various concentrations or ratios to improve protection from infection in children and young adults. In certain embodiments, viruses of the formulations are limited to dengue virus serotypes. Other embodiments concern methods of administering immunogenic compositions against dengue virus that can include chimeric dengue constructs and live, attenuated dengue viruses using single, dual or other regimens.
13
CN112638410A
诱导T细胞的疫苗组合物组合及其用途
Public
Publication/Patent Number: CN112638410A Publication Date: 2021-04-09 Application Number: 201980038045.9 Filing Date: 2019-04-04 Inventor: 伯特兰·乔治   斯科特·罗伯茨   Assignee: 艾尔特免疫公司   IPC: A61K39/12 Abstract: 本文提供了疫苗组合和用于在有相应需要的受试者中增强抗原特异性T细胞诱导的应答的方法。所述方法将全身性疫苗接种与第一组合物和/或第二组合物以及任选地第三组合物组合,所述第一组合物包含编码抗原或免疫原的非复制型病毒载体,所述抗原或免疫原包含一个或更多个CD8+ T细胞表位;所述第二组合物具有包含碳氟化合物连接的肽的胶束,其中每种与碳氟化合物连接的肽:i)长度为15个至75个氨基酸残基;ii)来自第一组合物的抗原或免疫原;并且iii)包含第一组合物的来自抗原或免疫原的一个或更多个CD8+ T细胞表位,以诱导抗原特异性CD8+ T细胞;所述第三组合物包含免疫调节剂组合物。
14
US2021187094A1
RAPID METHOD OF GENERATING LIVE ATTENUATED VACCINES
Publication/Patent Number: US2021187094A1 Publication Date: 2021-06-24 Application Number: 17/249,329 Filing Date: 2021-02-26 Inventor: Ooi, Eng Eong   Goh, Kenneth   Kwek, Swee Sen   Tang, Choon Kit   Assignee: NATIONAL UNIVERSITY OF SINGAPORE   IPC: A61K39/12 Abstract: The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.
15
US2021162036A1
IMPROVED DILUENT FOR CELL-ASSOCIATED ALPHAHERPESVIRUS VACCINE
Publication/Patent Number: US2021162036A1 Publication Date: 2021-06-03 Application Number: 16/771,022 Filing Date: 2018-12-19 Inventor: De, Groof Ad   Verstegen, Iwan   Assignee: Intervet Inc.   IPC: A61K39/12 Abstract: The present invention relates to the use of a diluent for the in-use stabilisation of cells infected with a cell-associated alphaherpesvims. Contrary to the long-standing practice of incorporating a considerable amount of peptone into the diluent for such virus-infected cells, it was found that a reduction of the amount of protein in the diluent improved the in-use stability of alphaherpesvirus-infected cells. Whereby the best stability was even obtained using a protein-free diluent. This effect was especially pronounced for recombinant HVT viruses expressing a heterologous insert. Being protein-free is highly advantageous for the production of the diluent, in respect of costs, safety, and consistency of production.
16
EP3474891B1
VACCINE COMPOSITIONS COMPRISING AN ATTENUATED MUTANT ZIKA VIRUS
Publication/Patent Number: EP3474891B1 Publication Date: 2021-01-20 Application Number: 17733424.0 Filing Date: 2017-06-22 Inventor: Despres, Philippe   Gadea, Gilles   Mavingui, Patrick   Viranaicken, Wildriss   Assignee: INSERM (Institut National de la Santé et de la Recherche Médicale)   Université de la Réunion Saint Denis   Institut de Recherche pour le Développement (IRD)   Centre National de la Recherche Scientifique (CNRS)   IPC: A61K39/12
17
EP3766518A1
PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS
Publication/Patent Number: EP3766518A1 Publication Date: 2021-01-20 Application Number: 20184598.9 Filing Date: 2006-12-28 Inventor: Roof, Michael B.   Hayes, Phillip Wayne   Eichmeyer, Mark   Nitzel, Greg   Schaeffer, Merrill   Assignee: Boehringer Ingelheim Animal Health USA Inc.   IPC: A61K39/12 Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
18
CN113194989A
初免-强化免疫接种方案
Public
Publication/Patent Number: CN113194989A Publication Date: 2021-07-30 Application Number: 201980084794.5 Filing Date: 2019-12-19 Inventor: E·斯特雷特   M·a·莫勒   P·基蒂坤   R·p·a·m·西格斯   E·范登博恩   Assignee: 英特维特国际股份有限公司   IPC: A61K39/12 Abstract: 本发明涉及一种免疫接种方法。具体地,本发明涉及一种用于保护目标动物免受由病毒引起的感染或疾病的初免‑强化免疫接种方案,其中所述免疫接种方案包括向所述目标动物施用包含所述病毒的活减毒形式的疫苗,然后向所述目标动物施用包含编码来自所述病毒的一种或多种抗原的RP的疫苗。
19
EP3849600A1
POLYMERSOMES COMPRISING A COVALENTLY BOUND ANTIGEN AS WELL AS METHODS OF MAKING AND USES THEREOF
Publication/Patent Number: EP3849600A1 Publication Date: 2021-07-21 Application Number: 19782906.2 Filing Date: 2019-09-12 Inventor: Nallani, Madhavan   Decaillot, Fabien   Cornell, Thomas Andrew   Khan, Amit Kumar   Assignee: ACM Biolabs Pte Ltd   IPC: A61K39/12
20
US2021244809A1
DEVELOPMENT OF A NOVEL LIVE ATTENUATED AFRICAN SWINE FEVER VACCINE BASED IN THE DELETION OF GENE I177L
Publication/Patent Number: US2021244809A1 Publication Date: 2021-08-12 Application Number: 17/223,252 Filing Date: 2021-04-06 Inventor: Gladue, Douglas P.   Borca, Manuel V.   Assignee: The United States of America, as represented by the Secretary of Agriculture   IPC: A61K39/12 Abstract: Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-GΔI1771 modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.
Total 500 pages